Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.32 |
| ▸ | UGCG | Q16739 | 4/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 2/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751530 | 0.88 | CETP (0.35) | BACE1BACE2UGCG | |
| SCHEMBL5752767 | 0.88 | CETP (0.35) | BACE1BACE2UGCG | |
| SCHEMBL1901641 | 0.88 | CETP (0.36) | BACE1BACE2PTGER4UGCG | |
| SCHEMBL1901640 | 0.88 | CETP (0.36) | BACE1BACE2PTGER4UGCG | |
| SCHEMBL5754682 | 0.87 | BACE1 (0.32) | BACE1BACE2PTGER4UGCG | |
| SCHEMBL5754604 | 0.85 | CETP (0.35) | BACE1UGCGMEN1KMT2A | |
| SCHEMBL5751713 | 0.84 | BACE1 (0.34) | BACE1BACE2PTGER4UGCGCTSL | |
| SCHEMBL1897534 | 0.84 | CETP (0.36) | BACE1UGCG | |
| SCHEMBL5754766 | 0.84 | BACE1 (0.34) | BACE1BACE2PTGER4UGCGHTT | |
| SCHEMBL5751109 | 0.84 | UGCG (0.39) | BACE1BACE2PTGER4UGCGACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | BACE1 835/4885BACE2 1392/4885PTGER4 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.